Drug intelligence / Profile preview

Shen'e Xiaozheng Formula

Development stage: Preclinical
Lead developer: Xiyuan Hospital
Administration: Oral

Overview

Shen'e Xiaozheng Formula is a Traditional Chinese Medicine (TCM) granule formulation developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is indicated for the treatment of unstable angina pectoris, particularly in patients presenting with the deficiency–blood stasis–toxicity syndrome. The formula is designed to improve myocardial ischemia and stabilize coronary plaques through multi-target mechanisms, including anti-inflammatory and anti-thrombotic effects. It is currently being evaluated in a randomized, double-blind, placebo-controlled Phase 0 clinical trial to assess its efficacy, safety, and proteomic impact.

Other names: Shen’e Xiaozheng FormulaShen’e Xiaozheng granules

Beyond the preview

Go deeper on Shen'e Xiaozheng Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shen'e Xiaozheng Formula.

Explore the full profile